Published in final edited form as:

Int J Cardiol. 2014 July 1; 174(3): 808–810. doi:10.1016/j.ijcard.2014.04.150.

Cigarette Smoking Among Patients with Chronic Diseases

**Tatiane da S. Campos^{1,2}, Kimber P. Richter³, A. Paula Cupertino³, Arise G. S. Galil^{1,2,4},
Eliane F. C. Banhato^{2,5}, Fernando A. B. Colugnati^{2,6}, and Marcus G. Batos^{2,6}**

Tatiane da S. Campos: tatynhasc@yahoo.com.br; Kimber P. Richter: krichter@kumc.edu; A. Paula Cupertino: acupertino@kumc.edu; Arise G. S. Galil: arise@cardiol.br; Eliane F. C. Banhato: ebanhato@gmail.com; Fernando A. B. Colugnati: fcolugnati@gmail.com; Marcus G. Batos: marcusgb@terra.com.br

¹Post-Graduate Program in Health, Federal University of Juiz de Fora, Juiz de Fora, MG, Brazil

²Foundation Institute of Minas in Research in Nephrology (IMEPEN), Rua José Lourenço Kelmer 1300, São Pedro 36036-330, Juiz de Fora, MG, Brazil

³Department of Preventive Medicine and Public Health, University of Kansas Medical Center KUMC), 3901 Rainbow Boulevard, Kansas City, Kansas, 66160, United States

⁴Municipal Prefecture of Juiz de Fora, Juiz de Fora, MG, Brazil

⁵Centro de Ensino Superior de Juiz de Fora

⁶Department of Clinical Medicine, Federal University of Juiz de Fora, MG, Brazil

Keywords

Tobacco; cigarettes; hypertension; diabetes; renal disease; kidney disease; chronic disease; secondary prevention; epidemiology

Tobacco dependence and chronic diseases are highly prevalent and each are top causes of morbidity and mortality in the world.[1, 2] Tobacco use is also modifiable risk factor for many chronic diseases including cardiovascular disease, diabetes, and inflammatory diseases.[3–5] In a 1999–2008 sample of U.S. citizens, 26% of diabetics smoked; younger age, less education, more alcohol consumption less physical activity, and symptoms of major depression increased their odds for smoking.[6] The prevalence of smoking among people with other chronic diseases, and with overlapping chronic diseases, is less well documented. A better understanding of comorbid tobacco use and chronic illnesses is important for higher income countries, where both are highly prevalent, and is also vital for system planning in middle income countries, where tobacco use is prevalent[2] and the incidence of chronic illness is on the rise.[1]

For correspondence and reprint requests: Kimber P. Richter, PhD, MPH, Department of Preventive Medicine and Public Health, University of Kansas Medical Center, 3901 Rainbow Blvd, Kansas City, KS 66160-7313, (913) 588-2718; fax: (913) 588-2780; krichter@kumc.edu.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Declarations of Interest: The authors have no commercial associations, current or over the past 5 years, that might pose a conflict of interest. In addition, no financial disclosures were reported by the authors of this paper.

We conducted a population-based survey of all patients attending a leading regional center for chronic conditions—*Centro HIPERDIA Minas* in Juiz de Fora (CHDM-JF) in the state of Minas Gerais, Brazil. CHDM-JF is a leading public secondary care facility affiliated with UFJF. It focuses on interdisciplinary treatment of diabetes, hypertension, and chronic kidney disease (CKD). This type of center is the middle link in the universal health care system in Brazil, which consists of primary, secondary, and tertiary (hospital) care facilities.

All CHDM-JF patients with scheduled appointments over a 3-month period, who were older than 18 years, were eligible and invited to participate. At CHDM-JF all patients check in at a central reception area, and patients' progress through visits with the multidisciplinary treatment team is tracked in a central location. Brazilian research assistants (RAs) screened for eligibility, explained the purpose of the study, invited eligible patients to participate, collected written consent, and verbally administered the survey. All study procedures were approved by the ethics committees at the University of Kansas Medical Center (#12787) and the Federal University of Juiz de Fora (#283/2011).

The survey consisted of items from international health assessments and screenings that had been validated in Brazilian Portuguese.[7–11] Data were recorded by RAs on paper forms, double-data entered into REDCap, and downloaded into Stata for cleaning and analysis.[12, 13]

Analyses included descriptive statistics, chi-square tests and t-tests. Tobacco use patterns were examined by number of chronic diseases. The percentage of patients who met Brazilian treatment guideline criteria for cessation medication was calculated. Generalized Linear Models were used for analysis comparing patient characteristics according to number of chronic diseases. The survey was conducted in 2012 and analyzed in 2013.

Over the 3-month study period, nearly all eligible patients (1,584—98%) visiting the clinic participated in the survey. Smokers (N=160) had a very low level of education and high rates of depression (Table). Most were being seen for hypertension (58.8%), followed by diabetes (48.8%) and CKD (33.8%). Comorbid chronic disease was the norm: 38.1% reported they had 1, 53.1% reported they had 2, and 8.8% reported they had 3 (data not shown).

Patients were highly interested in quitting and most were daily but light smokers (Table). Nearly all (98.1%) lived with another smoker in the home. Although 87% had been advised to quit by a health professional in the past year, only half (56%) had been given any assistance to quit. Notably, only 6.3% received any medication in the past year. Patients with one chronic disease were significantly more interested in receiving tobacco treatment through CHDM-JF (73.8%) compared to those with two (61.2%), or three chronic illnesses (50%) ($p=0.048$).

Most (65%) were interest in receiving treatment for tobacco dependence at CHDM-JF; interest was higher among those with 1 chronic illness (73.8%) compared to those with 2 (61.2%) or 3 (50%) ($p=0.048$). Most (77.5%) participants met at least one criterion for receiving cessation medication (Table).

This study found that one in ten patients being treated for chronic diseases smoked cigarettes. These patients were light but daily smokers and lived with another smoker in the home. Although most had been advised to quit, very few received evidence-based tobacco treatment—consisting of counseling and medication. Interest in receiving treatment via the chronic disease clinic was lower for sicker patients—those with multiple chronic illnesses.

The Brazilian context of this study is in some ways different but also similar to conditions in other countries. Brazilian treatment guidelines are evidence-based and accord with those in the U.S. and many other countries. These guidelines include identifying smokers; assessing readiness to quit; providing counseling and medication to those who are ready to quit; and scheduling follow-up.[14] Unlike the U.S., but similar to other countries, Brazil has a national strategy and public funding for provider training and the provision of counseling and medications.[15] Hence, the generalizability of these data must be weighed by each country's smoking and treatment context, and the clinic sample.

For example, the prevalence of smoking in this clinic population was approximately half of the Brazilian general population, which was 17.1% in 2008.[16, 17] However, Clair and colleagues found that tobacco use among U.S. diabetics, drawn from a nationally representative sample, was no different from the general population.[6] Interestingly, both studies found depression was prevalent among smokers with diabetes in both countries.

Strengths of this study include the high response rate, use of standardized international survey items, and rigorous methods for RA training and data entry. Limitations include the brief data collection instrument, which facilitated data collection but reduced the depth of measures; and collecting data in only one clinic site, which limits generalizability within and outside of Brazil.

These data suggest that much can be done to close the gap between simply advising patients with chronic diseases to quit—and actually helping them to do so. Tobacco dependence should be redefined as a co-occurring and highly treatable chronic disease[18–20], equal in importance to patients' other chronic conditions. Couples treatment could be offered to patients that live with other smokers. Chronic disease care providers should employ systems that ensure routine, evidence-based tobacco treatment and address comorbidities such as co-occurring depression and alcohol use.

Acknowledgments

The authors gratefully acknowledge the staff and patients of the CHDM-JF for facilitating this research.

This study was funded by the National Institutes of Health Fogarty International Center (R03TW008723).

References

1. World Health Organization. Global Status Report on Noncommunicable Diseases 2010. Geneva: World Health Organization; 2011.
2. World Health Organization. WHO Report on the Global Tobacco Epidemic, 2008: The MPOWER package. Geneva: World Health Organization; 2008.
3. U.S. Department of Health and Human Services. How Tobacco Smoke Causes Disease: The Biology and Behavioral Basis for Smoking-Attributable Disease: A Report of the Surgeon General. Atlanta,

GA: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health; 2010.

4. Johannsen A, Susin C, Gustafsson A. Smoking and inflammation: evidence for a synergistic role in chronic disease. *Periodontology* 2000. 2014; 64:111–126. [PubMed: 24320959]
5. Erhardt L. Cigarette smoking: an undertreated risk factor for cardiovascular disease. *Atherosclerosis*. 2009; 205:23–32. [PubMed: 19217623]
6. Clair C, Meigs JB, Rigotti NA. Smoking behavior among US adults with diabetes or impaired fasting glucose. *Am J Med*. 2013; 126:541, e15–e18. [PubMed: 23597801]
7. Giovino GA, Mirza SA, Samet JM, Gupta PC, Jarvis MJ, Bhala N, et al. Tobacco use in 3 billion individuals from 16 countries: an analysis of nationally representative cross-sectional household surveys. *Lancet*. 2012; 380:668–679. [PubMed: 22901888]
8. Fagerstrom KO, Schneider NG. Measuring nicotine dependence: a review of the Fagerstrom Tolerance Questionnaire. *J Behav Med*. 1989; 12:159–182. [PubMed: 2668531]
9. Lowe B, Kroenke K, Grafe K. Detecting and monitoring depression with a two-item questionnaire (PHQ-2). *J Psychosom Res*. 2005; 58:163–171. [PubMed: 15820844]
10. Bush K, Kivlahan DR, McDonell MB, Fihn SD, Bradley KA. The AUDIT alcohol consumption questions (AUDIT-C): an effective brief screening test for problem drinking. Ambulatory Care Quality Improvement Project (ACQUIP). Alcohol Use Disorders Identification Test. *Arch Intern Med*. 1998; 158:1789–1795. [PubMed: 9738608]
11. Meneses-Gaya, C. Validation Study of Instruments Assessing Depression Symptoms and Abuse and Dependence of Alcohol and Tobacco Ribeirão Preto: University of São Paulo. 2011.
12. Harris P, Taylor R, Thielke R, Payne J, Gonzalez N, Conde G. Research electronic data capture (REDCap) - A metadata-driven methodology and workflow process for providing translational research informatics support. *J Biomed Inform*. 2009; 42:377–381. [PubMed: 18929686]
13. StataCorp. Stata Statistical Software: Release 12. College Station, TX: StataCorp LP; 2011.
14. Reichert J, Araujo AJ, Goncalves CM, Godoy I, Chatkin JM, Sales MP, et al. Smoking cessation guidelines--2008. *Jornal brasileiro de pneumologia : publicacao oficial da Sociedade Brasileira de Pneumologia e Tisiologia*. 2008; 34:845–880. [PubMed: 19009219]
15. Instituto Nacional de Câncer. Plano de Implantação da Abordagem e Tratamento do Tabagismo na Rede SUS. Rio de Janeiro. 2004
16. Szklo AS, de Almeida LM, Figueiredo VC, Autran M, Malta D, Caixeta R, et al. A snapshot of the striking decrease in cigarette smoking prevalence in Brazil between 1989 and 2008. *Prev Med*. 2012; 54:162–167. [PubMed: 22182479]
17. Brazilian National Cancer Institute. Global Adult Tobacco Survey: Brazil report.
18. McLellan AT, Lewis DC, O'Brien CP, Kleber HD. Drug dependence, a chronic medical illness: implications for treatment, insurance, and outcomes evaluation. *JAMA*. 2000; 284:1689–1695. [PubMed: 11015800]
19. Joseph AM, Fu SS, Lindgren B, Rothman AJ, Kodl M, Lando H, et al. Chronic disease management for tobacco dependence: a randomized, controlled trial. *Arch Intern Med*. 2011; 171:1894–1900. [PubMed: 22123795]
20. Ellerbeck EF, Mahnken JD, Cupertino AP, Cox LS, Greiner KA, Mussulman LM, et al. Effect of varying levels of disease management on smoking cessation: a randomized trial. *Ann Intern Med*. 2009; 150:437–446. [PubMed: 19349629]

Table

Sample, Smoking Patterns and History, and Medication Eligibility (N =160)

Sociodemographics^a	
Age mean (SD)	55.24 ($\pm$ 11.69)
Female	86 (53.8%)
Education	
Less than elementary/middle school (<8 grades)	114 (71.3%)
Middle school (8 grades)	14 (8.8%)
High school	26 (16.3%)
Technical school	3 (1.9%)
University degree	2 (1.3%)
Post-graduate education	1 (0.6%)
Medical History	
Receiving treatment from CHDM-JF for:	
Hypertension	94 (58.8%)
Diabetes	78(48.8%)
Chronic renal disease	54 (33.8%)
Mental Health Comorbidities	
PHQ-2: Depression	72 (45%)
AUDIT-C: High risk drinking ^b	21 (13.12%)
Smoking History^c	
	N=160^d
Age started smoking, mean (SD) (N=159)	16.66 ($\pm$ 7.95)
Current Cigarettes Per Day, mean (SD)	14.1 ($\pm$ 9.02)
Light smokers (10 cigarettes per day)	51.88%
Daily smoker (smoked every day, past 30 days)	141 (88.13%)
Fagerström Test for Nicotine Dependence (FTND), mean (SD)	4.3 ($\pm$ 2.1)
Carbon Monoxide, parts per million mean (SD)	12.41 ($\pm$ 6.62)
Additional use of other forms of tobacco	
Hand-rolled cigarettes	12 (7.5%)
“Palha” cigarettes (cottage-industry rolled, in corn husk)	12 (7.5%)
Other (e.g, chewing tobacco, snuff, Bidis, pipes, cigars)	5 (3.1%)
Rules about smoking in the home	
Smoking is allowed in home	73 (45.6%)

Sociodemographics^a	
Smoking is not allowed in home, with exceptions	10 (6.3%)
Smoking is not allowed in home	71 (44.4%)
Have no rule	6 (3.8%)
At least one other smoker lives in patients' home	157 (98.1%)
Exposure to Health Professionals/Advice to Quit	
Not counting today, in the past 12 months...	
Visited a health professional 3 or more times	144 (90%)
Was asked smoking status by a health professional	142 (88.8%)
Was advised to quit smoking by a health professional	139 (86.9%)
Interest / Confidence in Quitting	
0-10 Interest in quitting smoking (0=low; 10=high) mean (SD)	8.77 ($\pm$ 2.69)
0-10 Confidence in quitting (0=low; 10=high) mean (SD)	7.38 ($\pm$ 3.17)
Plans for quitting	
Planning to quit in the next month	56 (35%)
Planning to quit in the next 12 months	46 (28.8%)
Not interested in quitting smoking	35 (21.9%)
Other	23 (14.4%)
Quit Attempts	
Longest quit attempt, during lifetime (in days) mean (SD)	234 ($\pm$ 1029)
Tried to quit at least one time in past 12 months	85 (53.1%)
If so, longest quit attempt (in days) median (IQR) (N=80)	8 (49)
Received any assistance to quit in the past 12 months	90 (56%)
Types of assistance received:	
Counseling from a health professional	38 (23.8%)
Clinic with sessions for quitting smoking	15 (9.4%)
Cessation medication (patch, gum, or lozenge)	22 (13.8%)
Prescription cessation medications	10 (6.3%)
Introduction to <i>Quitting</i> program at CHDM-JF	58 (36.3%)
Other (telephone, homeopathy, acupuncture, herbs)	11 (6.88%)
Interest in Tobacco Treatment	
Interested in receiving treatment through CHDM-JF	104 (65%)
0-10 Interest in using medication to quit (0=low;10=high) mean (SD)	7.38 ($\pm$ 3.17)
Eligibility for Cessation Medication	

Sociodemographics^a	
Smokes 20 or more cigarettes per day	52 (32.5%)
Smokes first cigarette within 30 minutes of waking <i>and</i> smokes at least 10 cigarettes per day	98 (61.25%)
FTND score ^b 5	77 (48.12%)
Tried to quit using the public cognitive-behavioral program	15 (9.4%)
Total meeting criteria ^f	124 (77.5%)

^a No. (%) unless otherwise noted

^b AUDIT-C cutoff 5

^c No. (%) unless otherwise noted

^d N=160 unless otherwise noted

^e This excludes one criterion, *the patient does not have clinical contraindications*, which we were not able to assess during our survey. In addition, guidelines permit treatment professionals to deem patients eligible based on clinical judgment.

^f Patients must meet 1 or more criteria to be considered eligible